BRPC also benefits from collaboration with the Department of Pathology’s Precision Cancer Medicine Initiative Team. This team, co-led by BRPC’s Director Dr. McCall and the Associate Vice President for DukeHealth Clinical Laboratories Dr. Michael Datto, harnesses the power of pathology data to support cutting edge clinical and translational cancer research. This is done through support of the Duke Frameshift Molecular Registry of Tumors (Frameshift MRT) software, support of the Duke Molecular Tumor Board program. The team also supports Duke’s participation in the American Association for Cancer Research (AACR)’s Genomics Evidence Neoplasia Information Exchange (GENIE) project.
There is significant overlap in the data work of the BRPC and the PCMI teams. For this reason, the BRPC and PCMI teams regularly collaborate to optimize the clinical and pathologic annotation of biospecimens made available to researchers through BRPC/CHTN.
More information about this team can be found here.